Mechanism

Endpoint	TE [95% CI]	p val	I2	n	k
2 yr Death (all cause)	no data
myocardial infarction (fatal and non fatal)	0.58 [0.43 0.78]	p=0.04	0	6760	4	SPIRIT II, SPIRIT IV, SPIRIT III, COMPARE,
4 yr mortality from all causes	no data
cardiac death	0.94 [0.52 1.71]	p=1.00	0	6763	4	SPIRIT II, SPIRIT IV, SPIRIT III, COMPARE,
4 yr MI	no data
4 yr death or MI	no data
MACE	0.60 [0.49 0.74]	p=0.04	0	6760	4	SPIRIT II, SPIRIT IV, SPIRIT III, COMPARE,
2 yr MACE	0.66 [0.49 0.88]	p=0.04	0	1800	1	COMPARE,
target-vessel revascularization	0.58 [0.44 0.76]	p=0.04	0	5487	2	SPIRIT IV, COMPARE,
2 yr TLR	0.65 [0.49 0.87]	p=0.04	0	3687	1	SPIRIT IV,
4 yr TLR	no data
target lesion revascularisation	0.50 [0.38 0.66]	p=0.04	0	6763	4	SPIRIT II, SPIRIT IV, SPIRIT III, COMPARE,
CABG	0.35 [0.01 17.55]	p=1.00	0	300	1	SPIRIT II,
in-lesion binary restenosis	no data
angiographic restenosis	no data
All cause death	0.99 [0.64 1.53]	p=1.00	0	6463	3	SPIRIT IV, SPIRIT III, COMPARE,
Stent thrombosis (any, end of follow up)	0.31 [0.16 0.59]	p=0.04	0	6451	3	SPIRIT IV, SPIRIT III, COMPARE,
4y stent thrombosis (ARC)	0.39 [0.22 0.72]	p=0.04	0	6458	3	SPIRIT IV, SPIRIT III, COMPARE,
4 yr stent thrombosis	no data
Acute stent thrombosis (<=24h)	0.38 [0.11 1.29]	p=1.00	0	5787	3	SPIRIT II, SPIRIT IV, COMPARE,
sub acute stent thrombosis (1-30 days)	0.10 [0.02 0.47]	p=0.04	0	5787	3	SPIRIT II, SPIRIT IV, COMPARE,
late stent thrombosis (31days - 1year)	0.18 [0.03 1.03]	p=1.00	0	3987	2	SPIRIT II, SPIRIT IV,

Trial	Studied treatment	Control	Patients
SPIRIT II, 2006	everolimus eluting stent, XIENCE V	placitaxel eluting stent, TAXUS EXPRESS2	De novo lesions (maximim two)
SPIRIT IV, 2010	XIENCE V Everolimus Eluting Coronary Stent System	TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent System (TAXUS).	patients with de novo native coronary artery lesions and reference vessel diameters between 2.5 mm to 4.25 mm and lesion lengths <= 28 mm
SPIRIT III, 2008	everolimus-eluting stent, XIENCE V	paclitaxel-eluting stent, Taxus	lesions 28 mm or less in length and with reference vessel diameter between 2.5 and 3.75 m
COMPARE, 2009	polymer based, everolimus-eluting stent (Xience V)	polymer-based, paclitaxel-eluting stent (Taxus Liberte)	unselected patients

Everolimus eluting stent

all NS

Everolimus eluting stent

coronary artery disease, in unparticular patients

all NS

Everolimus eluting stent

myocardial infarction (fatal and non fatal) by 42% suggested

MACE by 40% suggested

2 yr MACE by 34% suggested

target-vessel revascularization by 42% suggested

2 yr TLR by 35% suggested

target lesion revascularisation by 50% suggested

Stent thrombosis (any, end of follow up) by 69% suggested

4y stent thrombosis (ARC) by 61% suggested

sub acute stent thrombosis (1-30 days) by 90% suggested

Endpoint	TE [95% CI]	p val	I2	n	k
2 yr Death (all cause)	no data
myocardial infarction (fatal and non fatal)	0.58 [0.43 0.78]	p=0.04	0	6760	4	SPIRIT II, SPIRIT IV, SPIRIT III, COMPARE,
4 yr mortality from all causes	no data
cardiac death	0.94 [0.52 1.71]	p=1.00	0	6763	4	SPIRIT II, SPIRIT IV, SPIRIT III, COMPARE,
4 yr MI	no data
4 yr death or MI	no data
MACE	0.60 [0.49 0.74]	p=0.04	0	6760	4	SPIRIT II, SPIRIT IV, SPIRIT III, COMPARE,
2 yr MACE	0.66 [0.49 0.88]	p=0.04	0	1800	1	COMPARE,
target-vessel revascularization	0.58 [0.44 0.76]	p=0.04	0	5487	2	SPIRIT IV, COMPARE,
2 yr TLR	0.65 [0.49 0.87]	p=0.04	0	3687	1	SPIRIT IV,
4 yr TLR	no data
target lesion revascularisation	0.50 [0.38 0.66]	p=0.04	0	6763	4	SPIRIT II, SPIRIT IV, SPIRIT III, COMPARE,
CABG	0.35 [0.01 17.55]	p=1.00	0	300	1	SPIRIT II,
in-lesion binary restenosis	no data
angiographic restenosis	no data
All cause death	0.99 [0.64 1.53]	p=1.00	0	6463	3	SPIRIT IV, SPIRIT III, COMPARE,
Stent thrombosis (any, end of follow up)	0.31 [0.16 0.59]	p=0.04	0	6451	3	SPIRIT IV, SPIRIT III, COMPARE,
4y stent thrombosis (ARC)	0.39 [0.22 0.72]	p=0.04	0	6458	3	SPIRIT IV, SPIRIT III, COMPARE,
4 yr stent thrombosis	no data
Acute stent thrombosis (<=24h)	0.38 [0.11 1.29]	p=1.00	0	5787	3	SPIRIT II, SPIRIT IV, COMPARE,
sub acute stent thrombosis (1-30 days)	0.10 [0.02 0.47]	p=0.04	0	5787	3	SPIRIT II, SPIRIT IV, COMPARE,
late stent thrombosis (31days - 1year)	0.18 [0.03 1.03]	p=1.00	0	3987	2	SPIRIT II, SPIRIT IV,

Trial	Studied treatment	Control	Patients
SPIRIT II, 2006	everolimus eluting stent, XIENCE V	placitaxel eluting stent, TAXUS EXPRESS2	De novo lesions (maximim two)
SPIRIT IV, 2010	XIENCE V Everolimus Eluting Coronary Stent System	TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent System (TAXUS).	patients with de novo native coronary artery lesions and reference vessel diameters between 2.5 mm to 4.25 mm and lesion lengths <= 28 mm
SPIRIT III, 2008	everolimus-eluting stent, XIENCE V	paclitaxel-eluting stent, Taxus	lesions 28 mm or less in length and with reference vessel diameter between 2.5 and 3.75 m
COMPARE, 2009	polymer based, everolimus-eluting stent (Xience V)	polymer-based, paclitaxel-eluting stent (Taxus Liberte)	unselected patients

Everolimus eluting stent

all NS

Everolimus eluting stent

coronary artery disease, in small vessels

MACE by 74% suggested

target-vessel revascularization by 80% suggested

target lesion revascularisation by 90% suggested

Paclitaxel

coronary artery disease, in all type of patients

MACE by 25% suggested

target-vessel revascularization by 38% suggested

2 yr TLR by 42% suggested

target lesion revascularisation by 52% suggested

in-lesion binary restenosis by 70% suggested

angiographic restenosis by 63% suggested

Endpoint	TE [95% CI]	p val	I2	n	k
2 yr Death (all cause)	0.83 [0.57 1.20]	p=1.00	0	3006	1	HORIZONS-AMI Stent,
myocardial infarction (fatal and non fatal)	1.01 [0.76 1.33]	p=1.00	0	8899	13	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER, PATENCY, SCORE, TAXUS V (all patients), TAXUS VI, PASSION, Erglis, HORIZONS-AMI Stent,
4 yr mortality from all causes	no data
cardiac death	1.67 [0.69 4.06]	p=1.00	0	1683	3	TAXUS IV, SCORE, Erglis,
4 yr MI	1.49 [0.72 3.09]	p=1.00	0	619	1	PASSION,
4 yr death or MI	no data
MACE	0.75 [0.65 0.86]	p=0.04	0	8319	12	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER, PATENCY, SCORE, TAXUS V (all patients), TAXUS VI, Erglis, HORIZONS-AMI Stent,
2 yr MACE	0.98 [0.77 1.25]	p=1.00	0	3006	1	HORIZONS-AMI Stent,
target-vessel revascularization	0.62 [0.53 0.74]	p=0.04	0	5742	4	TAXUS IV, SCORE, TAXUS V (all patients), HORIZONS-AMI Stent,
2 yr TLR	0.58 [0.44 0.76]	p=0.04	0	3006	1	HORIZONS-AMI Stent,
4 yr TLR	0.67 [0.39 1.16]	p=1.00	0	619	1	PASSION,
target lesion revascularisation	0.48 [0.40 0.58]	p=0.04	0	8214	11	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER, PATENCY, TAXUS V (all patients), PASSION, Erglis, HORIZONS-AMI Stent,
CABG	no data
in-lesion binary restenosis	0.30 [0.19 0.47]	p=0.04	0	1314	1	TAXUS IV,
angiographic restenosis	0.37 [0.33 0.43]	p=0.04	0	6737	11	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER, PATENCY, SCORE, TAXUS V (all patients), TAXUS VI, HORIZONS-AMI Stent,
All cause death	0.95 [0.70 1.28]	p=1.00	0	9044	14	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER, PATENCY, SCORE, TAXUS V (all patients), TAXUS VI, PASSION, HAAMU-STENT, Erglis, HORIZONS-AMI Stent,
Stent thrombosis (any, end of follow up)	1.01 [0.69 1.47]	p=1.00	0	8336	12	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER, PATENCY, SCORE, TAXUS V (all patients), TAXUS VI, HAAMU-STENT, HORIZONS-AMI Stent,
4y stent thrombosis (ARC)	no data
4 yr stent thrombosis	1.98 [0.67 5.84]	p=1.00	0	619	1	PASSION,
Acute stent thrombosis (<=24h)	3.01 [0.31 29.10]	p=1.00	0	1156	1	TAXUS V (all patients),
sub acute stent thrombosis (1-30 days)	0.61 [0.14 2.63]	p=1.00	0	2470	2	TAXUS IV, TAXUS V (all patients),
late stent thrombosis (31days - 1year)	1.61 [0.67 3.86]	p=1.00	0	3309	6	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER,

Trial	Studied treatment	Control	Patients
TAXUS I, 2003	TAXUS NIR	NIR stent	Stable or unstable AP, silent ischaemia; single de novo or restenotic coronary lesions
TAXUS II, 2003	TAXUS	NIR stent	Stable or unstable AP, silent ischaemia; single de novo target lesion with estimatedstenosis >50% and <99%,
TAXUS IV, 2004	TAXUS	EXPRESS	Stable or unstable AP, provokable ischaemia with a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm)
ASPECT, 2003	coated Supra-G stent	Supra-G stent	patientswith discrete coronary lesions (<15 mm in length, 2.25 to 3.5 mm in diameter)
ELUTES, 2004	coated V-Flex Plus	V-Flex Plus	single de novo type A or type B1 lesions 15 mm length in a nativecoronary artery
DELIVER, 2004	non-polymer-based paclitaxel-coated ACHIEVE stent	stainless steel Multi-Link (ML) PENTA stent	patients with focal de novo coronary lesions, <25 mm in length, in 2.5- to 4.0-mm vessels
PATENCY, 2002	Logic PTX paclitaxel Eluting CoronaryStents	uncoated control stents	Patients with de novo lesions of 2.7- to 4.0-mm diameter and 25-mm length received 3.0, 3.5, or 4.0 mm 10- or 15-mm
SCORE, 2004	QuaDDS stents (paclitaxel)	uncoated control stents	patients with focal, de novo coronary lesions
TAXUS V (all patients), 2005	TAXUS	bare metal EXPRESS-2	Stable or unstable AP, silent ischaemia with single coronary artery stenosis including complex or previously unstudied lesions (requiring 2.25-mm, 4.0-mm, and/or multiple stents)
TAXUS VI, 2005	TAXUS	Express2 stent	Stable or unstable AP, silent ischaemia with long, complex coronary artery lesions
PASSION, 2006	Taxus Express2	Express2 or Liberté	Myocardial Infarction with ST-Segment Elevation
HAAMU-STENT, 2006	Taxus Express	Bare-metal-stent	AMI - STEMI patients undergoing PCI
Erglis, 2007	IVUS-guided paclitaxel-eluting stent (Taxus Express) after lesion pre-treatment with cutting balloon	IVUS-guided bare-metal (Express or Liberte) after lesion pre-treatment with cutting balloon	percutaneous coronary intervention for unprotected left main artery stenosis
HORIZONS-AMI Stent, 2008	paclitaxel-eluting stents (Taxus)	BMS (Express)	ST-elevation myocardial infarction

Paclitaxel

all NS

Paclitaxel

sub acute stent thrombosis (1-30 days) by 496% adverse event

cardiac death by 82% suggested

MACE by 50% suggested

2 yr MACE by 44% suggested

2 yr TLR by 103% suggested

target lesion revascularisation by 132% suggested

CABG by 126% suggested

late stent thrombosis (31days - 1year) by 57% suggested

Paclitaxel

coronary artery disease, in unparticular patients

MACE by 34% suggested

target-vessel revascularization by 50% suggested

target lesion revascularisation by 72% suggested

in-lesion binary restenosis by 70% suggested

angiographic restenosis by 68% suggested

Endpoint	TE [95% CI]	p val	I2	n	k
2 yr Death (all cause)	no data
myocardial infarction (fatal and non fatal)	2.14 [0.93 4.93]	p=1.00	0	3583	8	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER, PATENCY, SCORE,
4 yr mortality from all causes	no data
cardiac death	1.60 [0.63 4.03]	p=1.00	0	1580	2	TAXUS IV, SCORE,
4 yr MI	no data
4 yr death or MI	no data
MACE	0.66 [0.54 0.82]	p=0.04	0	3608	8	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER, PATENCY, SCORE,
2 yr MACE	no data
target-vessel revascularization	0.50 [0.36 0.69]	p=0.04	0	1580	2	TAXUS IV, SCORE,
2 yr TLR	no data
4 yr TLR	no data
target lesion revascularisation	0.28 [0.19 0.42]	p=0.04	0	3344	7	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER, PATENCY,
CABG	no data
in-lesion binary restenosis	0.30 [0.19 0.47]	p=0.04	0	1314	1	TAXUS IV,
angiographic restenosis	0.32 [0.26 0.40]	p=0.04	0	2158	8	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER, PATENCY, SCORE,
All cause death	0.94 [0.45 1.94]	p=1.00	0	3583	8	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER, PATENCY, SCORE,
Stent thrombosis (any, end of follow up)	1.67 [0.75 3.72]	p=1.00	0	3583	8	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER, PATENCY, SCORE,
4y stent thrombosis (ARC)	no data
4 yr stent thrombosis	no data
Acute stent thrombosis (<=24h)	no data
sub acute stent thrombosis (1-30 days)	0.98 [0.14 6.87]	p=1.00	0	1314	1	TAXUS IV,
late stent thrombosis (31days - 1year)	1.61 [0.67 3.86]	p=1.00	0	3309	6	TAXUS I, TAXUS II, TAXUS IV, ASPECT, ELUTES, DELIVER,

Trial	Studied treatment	Control	Patients
TAXUS I, 2003	TAXUS NIR	NIR stent	Stable or unstable AP, silent ischaemia; single de novo or restenotic coronary lesions
TAXUS II, 2003	TAXUS	NIR stent	Stable or unstable AP, silent ischaemia; single de novo target lesion with estimatedstenosis >50% and <99%,
TAXUS IV, 2004	TAXUS	EXPRESS	Stable or unstable AP, provokable ischaemia with a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm)
ASPECT, 2003	coated Supra-G stent	Supra-G stent	patientswith discrete coronary lesions (<15 mm in length, 2.25 to 3.5 mm in diameter)
ELUTES, 2004	coated V-Flex Plus	V-Flex Plus	single de novo type A or type B1 lesions 15 mm length in a nativecoronary artery
DELIVER, 2004	non-polymer-based paclitaxel-coated ACHIEVE stent	stainless steel Multi-Link (ML) PENTA stent	patients with focal de novo coronary lesions, <25 mm in length, in 2.5- to 4.0-mm vessels
PATENCY, 2002	Logic PTX paclitaxel Eluting CoronaryStents	uncoated control stents	Patients with de novo lesions of 2.7- to 4.0-mm diameter and 25-mm length received 3.0, 3.5, or 4.0 mm 10- or 15-mm
SCORE, 2004	QuaDDS stents (paclitaxel)	uncoated control stents	patients with focal, de novo coronary lesions

Paclitaxel

coronary artery disease, in long or complex lesion

MACE by 30% suggested

target-vessel revascularization by 30% suggested

target lesion revascularisation by 45% suggested

angiographic restenosis by 57% suggested

Paclitaxel

sub acute stent thrombosis (1-30 days) by 496% adverse event

cardiac death by 82% suggested

MACE by 50% suggested

2 yr MACE by 44% suggested

2 yr TLR by 103% suggested

target lesion revascularisation by 132% suggested

CABG by 126% suggested

late stent thrombosis (31days - 1year) by 57% suggested

Paclitaxel

coronary artery disease, in acute myocardial infarction

target-vessel revascularization by 35% suggested

2 yr TLR by 42% suggested

target lesion revascularisation by 39% suggested

angiographic restenosis by 56% suggested

Paclitaxel

coronary artery disease, in diabetic patients

target lesion revascularisation by 59% suggested

angiographic restenosis by 83% suggested

Paclitaxel

all NS

Paclitaxel

coronary artery disease, in unprotected left main artery stenosis

target lesion revascularisation by 88% suggested

Paclitaxel

coronary artery disease, in in stent restenosis

all NS

Paclitaxel

coronary artery disease, in small vessels

all NS

Paclitaxel

coronary artery disease, in bypass graft lesion

target lesion revascularisation by 83% suggested

Sirolimus eluting stent

coronary artery disease, in in stent restenosis

MACE by 62% suggested

target-vessel revascularization by 65% suggested

Sirolimus eluting stent

MACE by 48% suggested

target-vessel revascularization by 50% suggested

target lesion revascularisation by 56% suggested

CABG by 92% suggested

Sirolimus eluting stent

all NS

Sirolimus eluting stent

coronary artery disease, in all type of patients

myocardial infarction (fatal and non fatal) by 33% suggested

MACE by 62% suggested

2 yr MACE by 44% suggested

target-vessel revascularization by 59% suggested

target lesion revascularisation by 74% suggested

CABG by 58% suggested

angiographic restenosis by 81% suggested

Endpoint	TE [95% CI]	p val	I2	n	k
2 yr Death (all cause)	no data
4 yr mortality from all causes	no data
myocardial infarction (fatal and non fatal)	0.67 [0.46 0.97]	p=0.04	0	4362	9	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS, SES-SMART, PRISON II, SESAMI, MISSION, BASKET-PROVE (SES),
cardiac death	0.62 [0.32 1.19]	p=1.00	0	1850	2	MISSION, BASKET-PROVE (SES),
4 yr MI	no data
4 yr death or MI	no data
MACE	0.38 [0.32 0.46]	p=0.04	0	5344	12	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS, SES-SMART, DIABETES, Pache et al, PRISON II, SCANDSTENT, SESAMI, MISSION, BASKET-PROVE (SES),
2 yr MACE	0.56 [0.42 0.75]	p=0.04	0	2568	3	DIABETES, DEBATER (SES vs BMS), BASKET-PROVE (SES),
target-vessel revascularization	0.41 [0.33 0.51]	p=0.04	0	4127	6	SIRIUS, PRISON II, TYPHOON, SESAMI, MISSION, BASKET-PROVE (SES),
2 yr TLR	1.11 [0.57 2.17]	p=1.00	0	310	2	DIABETES, GISSOC II,
4 yr TLR	no data
target lesion revascularisation	0.26 [0.20 0.33]	p=0.04	0	3884	12	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS, SES-SMART, DIABETES, Pache et al, PRISON II, SCANDSTENT, SESAMI, DECODE, MISSION,
CABG	0.42 [0.18 0.98]	p=0.04	0	2315	6	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS, SES-SMART, MISSION,
in-lesion binary restenosis	no data
angiographic restenosis	0.19 [0.15 0.24]	p=0.04	0	3895	13	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS, SES-SMART, DIABETES, PRISON II, SCANDSTENT, SESAMI, SCORPIUS, MISSION, GISSOC II, DEBATER (SES vs BMS),
All cause death	0.85 [0.59 1.21]	p=1.00	0	5976	13	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS, SES-SMART, Pache et al, PRISON II, SCANDSTENT, TYPHOON, SESAMI, DECODE, MISSION, BASKET-PROVE (SES),
Stent thrombosis (any, end of follow up)	0.81 [0.52 1.29]	p=1.00	0	5479	12	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS, SES-SMART, PRISON II, SCANDSTENT, TYPHOON, SESAMI, DECODE, MISSION, BASKET-PROVE (SES),
4y stent thrombosis (ARC)	0.73 [0.24 2.22]	p=1.00	0	2157	3	SESAMI, MISSION, BASKET-PROVE (SES),
4 yr stent thrombosis	no data
Acute stent thrombosis (<=24h)	0.98 [0.02 49.74]	p=1.00	0	1058	1	SIRIUS,
sub acute stent thrombosis (1-30 days)	0.73 [0.13 3.90]	p=1.00	0	468	2	DIABETES, MISSION,
late stent thrombosis (31days - 1year)	0.44 [0.11 1.76]	p=1.00	0	1906	5	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS, DIABETES,

Trial	Studied treatment	Control	Patients
Kochiadakis, 2007	sirolimus-eluting stents	bare metal stent	one-vesseldisease (>70% narrowing of the lumen of one major epicardialcoronary artery); stable coronary artery disease, age <70 years, and vessel referencediameter >=2.5 mm
RAVEL, 2002	coated Bx Velocity	Bx Velocity	Stable or unstable AP, silent ischaemia; single primary target lesion in a native coronary artery
SIRIUS, 2003	SES	Bx Velocity	Stable or unstable AP, signs of myocardial ischaemia
C-SIRIUS, 2004	coated Bx-VELOCITY	Bx-VELOCITY	Stable or unstable AP, silent ischaemia
E-SIRIUS, 2003	coated Bx Velocity	Bx Velocity	Stable or unstable AP, silent ischaemia; single-vessel or multivessel coronary disease but with only one new lesion with an estimated stenosis of more than 50% but less than 100% in a major native coronary artery requiring treatment
SES-SMART, 2004	Cypher	Bx Sonic	Stable AP, ACS, silent myocardial ischaemia as shown by exercise stress test
DIABETES, 2005	Cypher	Bx Velocity/Sonic	de novo lesions in native coronary arteriesin 1, 2, or 3 native vessels with symptoms or objective evidence of ischemia; vessel size smaller than 4.0 mm
Pache et al, 2005	Cypher	BeStent 2	with symptomatic coronary artery disease and significant angiographic stenosis in native coronary vessels
PRISON II, 2006	Cypher	BxVelocity	Chronic total occlusion, positive exercise stress test
SCANDSTENT, 2006	Cypher	Sonic	Stable or unstable AP, recent AMI (non ST-elevation); with one or more de novo complex lesions in native coronary vessels (occluded, bifurcational, ostial or angulated)
TYPHOON, 2006	Cypher or CypherSelect	any commerciallyavailable uncoated stent	AMI
SESAMI, 2007	Cypher	BX stent, Cordis	AMI
DECODE, 2005	CYPHER (Up to 3 stents per patient were allowed)	Bx VELOCITY (Up to 3 stents per patient were allowed)	Stable or unstable angina in diabetic patients with with up to 2 de novo lesions in up to 2 native coronary vessels
SCORPIUS, 2007	Cypher	Bx-Velocity	patients with diabetes and de novo coronary artery lesions
MISSION, 2008	Cypher	Vision	primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (<9h)
Ortolani et al, 2007	Cypher	Vision	symptomatic coronary artery disease and target vessel diameter appropriate for implantation a 3-mm stent
Pasceri, 2003	Cypher
GISSOC II, 2010	Sirolimus Eluting Stent	Bare Metal Stent	patients with Chronic Total Occlusion older than 1 month, and successful recanalization
DEBATER (SES vs BMS), 2009	sirolimus-eluting stents	bare-metal stents	patients undergoing PCI for STEMI withon 12 hours
BASKET-PROVE (SES), 2010	first-generation sirolimus-eluting stent	BMS	patients needing stents 3.0 mm or larger

Sirolimus eluting stent

target-vessel revascularization by 76% suggested

Sirolimus eluting stent

MACE by 25% suggested

target-vessel revascularization by 40% suggested

target lesion revascularisation by 31% suggested

angiographic restenosis by 32% suggested

4y stent thrombosis (ARC) by 33% suggested

Endpoint	TE [95% CI]	p val	I2	n	k
2 yr Death (all cause)	no data
4 yr mortality from all causes	no data
myocardial infarction (fatal and non fatal)	0.87 [0.70 1.09]	p=1.00	0	10073	20	TAXi, ISAR-DESIRE (SES vs PES), ISAR-DIABETES, SIRTAX (Windecker), CORPAL, REALITY, ISAR-SMART 3, Zhang (SES vs PES), LONG DES II, PROSIT, SORT OUT II, Cervinka, Petronio et al, Han, BASKET (vs paclitaxel), Di Lorenzo et al., ISAR-LEFT-MAIN, Kim, Pan, DES-DIABETES,
cardiac death	0.80 [0.43 1.50]	p=1.00	0	5668	6	SIRTAX (Windecker), REALITY, LONG DES II, PROSIT, SORT OUT II, DES-DIABETES,
4 yr MI	no data
4 yr death or MI	no data
MACE	0.75 [0.61 0.92]	p=0.04	0	6190	7	SIRTAX (Windecker), REALITY, Zhang (SES vs PES), PROSIT, SORT OUT II, ISAR-LEFT-MAIN, DES-DIABETES,
2 yr MACE	no data
target-vessel revascularization	0.60 [0.44 0.83]	p=0.04	0	5563	6	ISAR-DESIRE (SES vs PES), SIRTAX (Windecker), REALITY, LONG DES II, SORT OUT II, DES-DIABETES,
2 yr TLR	no data
4 yr TLR	no data
target lesion revascularisation	0.69 [0.57 0.83]	p=0.04	0	9266	18	BASKET (vs paclitaxel), Di Lorenzo et al., TAXi, ISAR-DIABETES, SIRTAX (Windecker), CORPAL, REALITY, ISAR-SMART 3, Zhang (SES vs PES), LONG DES II, PROSIT, SORT OUT II, Cervinka, Petronio et al, Han, Kim, Pan, DES-DIABETES,
CABG	1.28 [0.27 6.00]	p=1.00	0	771	3	TAXi, Kim, DES-DIABETES,
in-lesion binary restenosis	0.76 [0.57 1.02]	p=1.00	0	2311	2	REALITY, DES-DIABETES,
angiographic restenosis	0.68 [0.53 0.87]	p=0.04	0	3587	5	REALITY, LONG DES II, ISAR-LEFT-MAIN, Kim, DES-DIABETES,
All cause death	0.85 [0.66 1.11]	p=1.00	0	10523	21	TAXi, ISAR-DESIRE (SES vs PES), ISAR-DIABETES, SIRTAX (Windecker), CORPAL, REALITY, ISAR-SMART 3, Zhang (SES vs PES), LONG DES II, PROSIT, SORT OUT II, Cervinka, Petronio et al, Han, BASKET (vs paclitaxel), Di Lorenzo et al., ISAR-TEST-1, ISAR-LEFT-MAIN, Kim, Pan, DES-DIABETES,
Stent thrombosis (any, end of follow up)	0.81 [0.57 1.14]	p=1.00	0	9508	18	TAXi, ISAR-DESIRE (SES vs PES), ISAR-DIABETES, SIRTAX (Windecker), CORPAL, REALITY, ISAR-SMART 3, Zhang (SES vs PES), LONG DES II, PROSIT, SORT OUT II, Cervinka, Petronio et al, Han, BASKET (vs paclitaxel), Di Lorenzo et al., ISAR-TEST-1, DES-DIABETES,
4y stent thrombosis (ARC)	0.67 [0.47 0.96]	p=0.04	0	8692	16	TAXi, ISAR-DESIRE (SES vs PES), ISAR-DIABETES, SIRTAX (Windecker), CORPAL, REALITY, ISAR-SMART 3, Zhang (SES vs PES), LONG DES II, PROSIT, SORT OUT II, Cervinka, Petronio et al, Han, BASKET (vs paclitaxel), Di Lorenzo et al.,
4 yr stent thrombosis	no data
Acute stent thrombosis (<=24h)	0.63 [0.16 2.47]	p=1.00	0	2061	3	REALITY, PROSIT, DES-DIABETES,
sub acute stent thrombosis (1-30 days)	0.44 [0.13 1.45]	p=1.00	0	2061	3	REALITY, PROSIT, DES-DIABETES,
late stent thrombosis (31days - 1year)	0.81 [0.14 4.56]	p=1.00	0	2311	4	ISAR-DIABETES, REALITY, PROSIT, DES-DIABETES,

Trial	Studied treatment	Control	Patients
Tomai, 2008	sirolimus-eluting stent	paclitaxel-eluting stent	diabetic patient with multiple de novo coronary artery lesions
TAXi, 2005	Cypher	Taxus	Unselected patients
ISAR-DESIRE (SES vs PES), 2005	Cypher	Taxus	In-stent restenosis. AP and/or positive test, previously stented, no AMI
ISAR-DIABETES, 2005	Taxus	Cypher	Diabetic patients. AP or positive stress, no AMI with clinically significant angiographic stenosis in a native coronary vessel
SIRTAX (Windecker), 2005	sirolimus-eluting stents (Cypher)	paclitaxel-eluting stents (Taxus)	Unselected patients. Stable AP, ACS, including AMI. at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation
CORPAL, 2005	sirolimus	paclitaxel	Documented myocardial ischaemia, no AMI
REALITY, 2006	Cypher	Taxus	Relatively unselected patients. Stable or unstable documented silent ischaemia, no AMI with 1 or 2 de novo lesions (2.25-3.00 mm in diameter) in native coronary arteries
ISAR-SMART 3, 2006	Taxus	Cypher	Small vessels, de novo lesions in native coronary vessels with a diameter of <2.80 mm nondiabetic patients. AP or positive stress, no AMI
Zhang (SES vs PES), 2006	Cypher	Taxus	Unselected patients. Stable or unstable AP, ACS with de novo coronary lesions
LONG DES II, 2006	SES	PES	Long lesions. AP or positive stress, no AMI
PROSIT, 2006	SES Cordis	PES Boston Scientific	AMI or persistent ischaemia 12-24h
SORT OUT II, 2008	Cypher stent	Taxus stent(Boston Scientific Corp)	Unselected patients (included ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris, and stable angina)
Cervinka, 2006	sirolimus-eluting stent	paclitaxel-eluting stent	Complex lesionsand patients. Signs and/or symptoms myocardial ischaemia, including AMI
Petronio et al, 2007	Cypher	Taxus	Complex lesions. Stable AP or documented ischaemia, no AMI
Han, 2006	Cypher	Taxus	Multivessel disease. Stable or unstable AP, no AMI
BASKET (vs paclitaxel), 2005	Cypher	Taxus	Unselected patients; de-novo lesions
Di Lorenzo et al., 2005	sirolimus	paclitaxel	ST-segment elevation myocardial infarction
ISAR-TEST-1, 2006	rapamycin-eluting stent Yukon	Taxus	stable or unstable anginaor a positive stress test, stable or unstable anginaor a positive stress test
ISAR-LEFT-MAIN, 2009	Paclitaxel-eluting stent	Sirolimus-eluting stent	Unprotected Left Main Coronary Artery Disease
Kim, 2008	Cypher	Taxus	Korean diabetic patients with high-grade de novo coronary lesions (stenosis of>70 percent of the luminal diameter) requiring <3 stents
Pan, 2007	SES for provisional T-stenting	PES for provisional T-stenting	patients with bifurcation lesions
DES-DIABETES, 2008	sirolimus-eluting stent	paclitaxel-elutingstent	diabetic patients with angina pectoris and/or a positive stress test and a native coronary lesion

Sirolimus eluting stent

all NS

Sirolimus eluting stent

all NS

Sirolimus eluting stent

coronary artery disease, in diabetic patients

MACE by 55% suggested

2 yr MACE by 69% suggested

target-vessel revascularization by 75% suggested

2 yr TLR by 78% suggested

target lesion revascularisation by 75% suggested

angiographic restenosis by 88% suggested

Endpoint	TE [95% CI]	p val	I2	n	k
2 yr Death (all cause)	no data
myocardial infarction (fatal and non fatal)	0.80 [0.37 1.75]	p=1.00	0	212	2	SES-SMARt (diabetics), DESSERT,
4 yr mortality from all causes	no data
cardiac death	no data
4 yr MI	no data
4 yr death or MI	no data
MACE	0.45 [0.27 0.74]	p=0.04	0	372	3	DIABETES, SES-SMARt (diabetics), DESSERT,
2 yr MACE	0.31 [0.14 0.69]	p=0.04	0	158	1	DIABETES,
target-vessel revascularization	0.25 [0.09 0.70]	p=0.04	0	138	1	DESSERT,
2 yr TLR	0.22 [0.08 0.57]	p=0.04	0	158	1	DIABETES,
4 yr TLR	no data
target lesion revascularisation	0.25 [0.15 0.40]	p=0.04	0	499	5	DIABETES, DECODE, Ravel (diabetics), SES-SMARt (diabetics), DESSERT,
CABG	1.03 [0.02 52.63]	p=1.00	0	138	1	DESSERT,
in-lesion binary restenosis	no data
angiographic restenosis	0.12 [0.06 0.24]	p=0.04	0	278	3	DIABETES, Ravel (diabetics), SES-SMARt (diabetics),
All cause death	0.72 [0.17 2.93]	p=1.00	0	295	3	DECODE, SES-SMARt (diabetics), DESSERT,
Stent thrombosis (any, end of follow up)	0.80 [0.15 4.26]	p=1.00	0	295	3	DECODE, SES-SMARt (diabetics), DESSERT,
4y stent thrombosis (ARC)	no data
4 yr stent thrombosis	no data
Acute stent thrombosis (<=24h)	1.03 [0.02 52.63]	p=1.00	0	138	1	DESSERT,
sub acute stent thrombosis (1-30 days)	1.03 [0.11 9.99]	p=1.00	0	296	2	DIABETES, DESSERT,
late stent thrombosis (31days - 1year)	0.34 [0.04 3.33]	p=1.00	0	296	2	DIABETES, DESSERT,

Trial	Studied treatment	Control	Patients
DIABETES, 2005	Cypher	Bx Velocity/Sonic	de novo lesions in native coronary arteriesin 1, 2, or 3 native vessels with symptoms or objective evidence of ischemia; vessel size smaller than 4.0 mm
DECODE, 2005	CYPHER (Up to 3 stents per patient were allowed)	Bx VELOCITY (Up to 3 stents per patient were allowed)	Stable or unstable angina in diabetic patients with with up to 2 de novo lesions in up to 2 native coronary vessels
Ravel (diabetics), 2004	coated Bx velocity	Bx VELOCITY	sub groups of diabetic patients with de novo native coronary arterylesions 2.5 to 3.5 mm in diameter by visualassessment that could be covered by an 18-mm stent
SES-SMARt (diabetics), 2005	Cypher	Bx Sonic	Diabetic patients with de novo target lesion <=2.75 mm in diameter in a native coronary artery that could be completely covered by a single stent (maximum length 33 mm)
DESSERT, 2008	Cypher andCypher Select	Sonic (Cordis)	de novo lesions of diabetic patients treated with insulin and/or oral antidiabetics for >3 months
SIRIUS (diabetics), 2003	SES	BMS	sub group of diabetics patients of SIRIUS study

Sirolimus eluting stent

target lesion revascularisation by 36% suggested

in-lesion binary restenosis by 79% suggested

angiographic restenosis by 75% suggested

Endpoint	TE [95% CI]	p val	I2	n	k
2 yr Death (all cause)	no data
4 yr mortality from all causes	no data
myocardial infarction (fatal and non fatal)	1.39 [0.43 4.47]	p=1.00	0	819	3	ISAR-DIABETES, Kim, DES-DIABETES,
cardiac death	0.33 [0.01 8.23]	p=1.00	0	400	1	DES-DIABETES,
4 yr MI	no data
4 yr death or MI	no data
MACE	0.41 [0.16 1.07]	p=1.00	0	469	2	TAxi (diabetics), DES-DIABETES,
2 yr MACE	no data
target-vessel revascularization	0.44 [0.18 1.09]	p=1.00	0	400	1	DES-DIABETES,
2 yr TLR	no data
4 yr TLR	no data
target lesion revascularisation	0.64 [0.40 1.00]	p=0.04	0	1468	6	ISAR-DIABETES, SIRTAX diabetics, Kim, TAxi (diabetics), REALITY (diabetics), DES-DIABETES,
CABG	1.00 [0.17 5.81]	p=1.00	0	569	2	Kim, DES-DIABETES,
in-lesion binary restenosis	0.21 [0.09 0.53]	p=0.04	0	400	1	DES-DIABETES,
angiographic restenosis	0.25 [0.12 0.52]	p=0.04	0	569	2	Kim, DES-DIABETES,
All cause death	0.65 [0.22 1.96]	p=1.00	0	819	3	ISAR-DIABETES, Kim, DES-DIABETES,
Stent thrombosis (any, end of follow up)	0.72 [0.08 6.58]	p=1.00	0	650	2	ISAR-DIABETES, DES-DIABETES,
4y stent thrombosis (ARC)	0.20 [0.01 4.21]	p=1.00	0	250	1	ISAR-DIABETES,
4 yr stent thrombosis	no data
Acute stent thrombosis (<=24h)	3.00 [0.12 74.09]	p=1.00	0	400	1	DES-DIABETES,
sub acute stent thrombosis (1-30 days)	1.00 [0.02 50.65]	p=1.00	0	400	1	DES-DIABETES,
late stent thrombosis (31days - 1year)	0.47 [0.14 1.62]	p=1.00	0	1230	4	ISAR-DIABETES, SIRTAX diabetics, REALITY (diabetics), DES-DIABETES,

Trial	Studied treatment	Control	Patients
Tomai, 2008	sirolimus-eluting stent	paclitaxel-eluting stent	diabetic patient with multiple de novo coronary artery lesions
ISAR-DIABETES, 2005	Taxus	Cypher	Diabetic patients. AP or positive stress, no AMI with clinically significant angiographic stenosis in a native coronary vessel
SIRTAX diabetics, 2005	Cypher	Taxus	Sub groups of diabetics patients with either stable angina or an acute coronary syndrome
Kim, 2008	Cypher	Taxus	Korean diabetic patients with high-grade de novo coronary lesions (stenosis of>70 percent of the luminal diameter) requiring <3 stents
TAxi (diabetics), 3000	SES	PES
REALITY (diabetics), 2006	SES	PES
DES-DIABETES, 2008	sirolimus-eluting stent	paclitaxel-elutingstent	diabetic patients with angina pectoris and/or a positive stress test and a native coronary lesion

Sirolimus eluting stent

coronary artery disease, in unparticular patients

MACE by 60% suggested

target-vessel revascularization by 59% suggested

target lesion revascularisation by 74% suggested

angiographic restenosis by 81% suggested

Endpoint	TE [95% CI]	p val	I2	n	k
2 yr Death (all cause)	no data
4 yr mortality from all causes	no data
myocardial infarction (fatal and non fatal)	0.98 [0.57 1.69]	p=1.00	0	1748	4	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS,
cardiac death	no data
4 yr MI	no data
4 yr death or MI	no data
MACE	0.40 [0.31 0.52]	p=0.04	0	2248	5	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS, Pache et al,
2 yr MACE	no data
target-vessel revascularization	0.41 [0.29 0.60]	p=0.04	0	1058	1	SIRIUS,
2 yr TLR	no data
4 yr TLR	no data
target lesion revascularisation	0.26 [0.19 0.37]	p=0.04	0	2248	5	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS, Pache et al,
CABG	0.47 [0.16 1.35]	p=1.00	0	1748	4	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS,
in-lesion binary restenosis	no data
angiographic restenosis	0.19 [0.14 0.28]	p=0.04	0	1335	4	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS,
All cause death	1.42 [0.66 3.05]	p=1.00	0	2248	5	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS, Pache et al,
Stent thrombosis (any, end of follow up)	0.90 [0.26 3.11]	p=1.00	0	1748	4	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS,
4y stent thrombosis (ARC)	no data
4 yr stent thrombosis	no data
Acute stent thrombosis (<=24h)	0.98 [0.02 49.74]	p=1.00	0	1058	1	SIRIUS,
sub acute stent thrombosis (1-30 days)	no data
late stent thrombosis (31days - 1year)	0.46 [0.10 2.17]	p=1.00	0	1748	4	RAVEL, SIRIUS, C-SIRIUS, E-SIRIUS,

Trial	Studied treatment	Control	Patients
Kochiadakis, 2007	sirolimus-eluting stents	bare metal stent	one-vesseldisease (>70% narrowing of the lumen of one major epicardialcoronary artery); stable coronary artery disease, age <70 years, and vessel referencediameter >=2.5 mm
RAVEL, 2002	coated Bx Velocity	Bx Velocity	Stable or unstable AP, silent ischaemia; single primary target lesion in a native coronary artery
SIRIUS, 2003	SES	Bx Velocity	Stable or unstable AP, signs of myocardial ischaemia
C-SIRIUS, 2004	coated Bx-VELOCITY	Bx-VELOCITY	Stable or unstable AP, silent ischaemia
E-SIRIUS, 2003	coated Bx Velocity	Bx Velocity	Stable or unstable AP, silent ischaemia; single-vessel or multivessel coronary disease but with only one new lesion with an estimated stenosis of more than 50% but less than 100% in a major native coronary artery requiring treatment
Pache et al, 2005	Cypher	BeStent 2	with symptomatic coronary artery disease and significant angiographic stenosis in native coronary vessels
Ortolani et al, 2007	Cypher	Vision	symptomatic coronary artery disease and target vessel diameter appropriate for implantation a 3-mm stent

Sirolimus eluting stent

all NS

Endpoint	TE [95% CI]	p val	I2	n	k
2 yr Death (all cause)	no data
myocardial infarction (fatal and non fatal)	0.79 [0.58 1.08]	p=1.00	0	6075	7	TAXi, SIRTAX (Windecker), REALITY, Zhang (SES vs PES), SORT OUT II, Han, BASKET (vs paclitaxel),
4 yr mortality from all causes	no data
cardiac death	0.89 [0.41 1.93]	p=1.00	0	4463	3	SIRTAX (Windecker), REALITY, SORT OUT II,
4 yr MI	no data
4 yr death or MI	no data
MACE	0.78 [0.61 1.01]	p=1.00	0	4875	4	SIRTAX (Windecker), REALITY, Zhang (SES vs PES), SORT OUT II,
2 yr MACE	no data
target-vessel revascularization	0.76 [0.50 1.13]	p=1.00	0	4463	3	SIRTAX (Windecker), REALITY, SORT OUT II,
2 yr TLR	no data
4 yr TLR	no data
target lesion revascularisation	0.84 [0.64 1.09]	p=1.00	0	6075	7	BASKET (vs paclitaxel), TAXi, SIRTAX (Windecker), REALITY, Zhang (SES vs PES), SORT OUT II, Han,
CABG	2.94 [0.12 73.07]	p=1.00	0	202	1	TAXi,
in-lesion binary restenosis	0.88 [0.65 1.19]	p=1.00	0	1911	1	REALITY,
angiographic restenosis	0.86 [0.61 1.22]	p=1.00	0	1911	1	REALITY,
All cause death	0.96 [0.63 1.47]	p=1.00	0	6525	8	TAXi, SIRTAX (Windecker), REALITY, Zhang (SES vs PES), SORT OUT II, Han, BASKET (vs paclitaxel), ISAR-TEST-1,
Stent thrombosis (any, end of follow up)	0.85 [0.58 1.23]	p=1.00	0	6488	8	TAXi, SIRTAX (Windecker), REALITY, Zhang (SES vs PES), SORT OUT II, Han, BASKET (vs paclitaxel), ISAR-TEST-1,
4y stent thrombosis (ARC)	0.72 [0.49 1.07]	p=1.00	0	6075	7	TAXi, SIRTAX (Windecker), REALITY, Zhang (SES vs PES), SORT OUT II, Han, BASKET (vs paclitaxel),
4 yr stent thrombosis	no data
Acute stent thrombosis (<=24h)	0.49 [0.09 2.68]	p=1.00	0	1353	1	REALITY,
sub acute stent thrombosis (1-30 days)	0.42 [0.11 1.63]	p=1.00	0	1353	1	REALITY,
late stent thrombosis (31days - 1year)	0.20 [0.01 4.08]	p=1.00	0	1353	1	REALITY,

Trial	Studied treatment	Control	Patients
TAXi, 2005	Cypher	Taxus	Unselected patients
SIRTAX (Windecker), 2005	sirolimus-eluting stents (Cypher)	paclitaxel-eluting stents (Taxus)	Unselected patients. Stable AP, ACS, including AMI. at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation
REALITY, 2006	Cypher	Taxus	Relatively unselected patients. Stable or unstable documented silent ischaemia, no AMI with 1 or 2 de novo lesions (2.25-3.00 mm in diameter) in native coronary arteries
Zhang (SES vs PES), 2006	Cypher	Taxus	Unselected patients. Stable or unstable AP, ACS with de novo coronary lesions
SORT OUT II, 2008	Cypher stent	Taxus stent(Boston Scientific Corp)	Unselected patients (included ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris, and stable angina)
Han, 2006	Cypher	Taxus	Multivessel disease. Stable or unstable AP, no AMI
BASKET (vs paclitaxel), 2005	Cypher	Taxus	Unselected patients; de-novo lesions
ISAR-TEST-1, 2006	rapamycin-eluting stent Yukon	Taxus	stable or unstable anginaor a positive stress test, stable or unstable anginaor a positive stress test
Wessely, 2008	rapamycin polymer-coated drug-eluting stent	paclitaxel polymer-coated drug-eluting stent